Will new capsule launch in US boost Lupin?

| Updated on October 04, 2019 Published on October 04, 2019

Lupin has launched Mycophenolate Mofetil Capsules USP, 250 mg in the US. Lupin’s alliance partner Concord Biotech had received approval from the USFDA earlier.

These capsules are an anti-metabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants and should be used in combination with other immunosuppressants. Mycophenolate Mofetil Capsules had annual sales of about $53 million in the US.

Published on October 04, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.